RNAi therapeutics: an antiviral strategy for human infections

Download
Citations
Altmetric
Author
Kelleher, AD; Cortez-Jugo, C; Cavalieri, F; Qu, Y; Glanville, AR; Caruso, F; Symonds, G; Ahlenstiel, CLDate
2020-10Source Title
Current Opinion in PharmacologyPublisher
Elsevier BVUniversity of Melbourne Author/s
Caruso, Francesco; Cortez-Jugo, Christina; Cavalieri, Francesca; Qu, YijiaoAffiliation
Chemical and Biomolecular EngineeringMetadata
Show full item recordDocument Type
Journal ArticleCitations
Kelleher, A. D., Cortez-Jugo, C., Cavalieri, F., Qu, Y., Glanville, A. R., Caruso, F., Symonds, G. & Ahlenstiel, C. L. (2020). RNAi therapeutics: an antiviral strategy for human infections. Current Opinion in Pharmacology, 54, pp.121-129. https://doi.org/10.1016/j.coph.2020.09.011.Access Status
Open AccessOpen Access URL
https://doi.org/10.1016/j.coph.2020.09.011Abstract
Gene silencing induced by RNAi represents a promising antiviral development strategy. This review will summarise the current state of RNAi therapeutics for treating acute and chronic human virus infections. The gene silencing pathways exploited by RNAi therapeutics will be described and include both classic RNAi, inducing cytoplasmic mRNA degradation post-transcription and novel RNAi, mediating epigenetic modifications at the transcription level in the nucleus. Finally, the challenge of delivering gene modifications via RNAi will be discussed, along with the unique characteristics of respiratory versus systemic administration routes to highlight recent advances and future potential of RNAi antiviral treatment strategies.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References